

**REMARKS**

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a disk copy of the Substitute Sequence Listing. The disk copy of the Substitute Sequence Listing, file "2006-06-05 0760-0343PUS1.ST25.txt", **is identical to the paper copy**, except that it lacks formatting.

The Sequence Listing is amended in response to the Raw Sequence Listing Error Report. Specifically, the siRNA sequences presented as SEQ ID NOS: 20-25 are changed from RNA to DNA in order to present both thymine (t) and uracil (u) in the same sequence as suggested by the USPTO in the Error Report. The description for each siRNA sequence is also amended pursuant to the Sequence Listing Error Report. No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,  
BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Andrew D. Meikle, #32,868

ADM/psq  
0760-0343PUS1

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachments:                      Disk and paper copy of the Sequence Listing  
    Copy of Notification